Showing results (41-50 of 49) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
CPT: Pharmacometrics & Systems Pharmacology|February 18, 2020
Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology ModelingVictor Sokolov, Tatiana Yakovleva, Lulu Chu, et al.The Journal of Pharmacology and Experimental Therapeutics|August 9, 2020
Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical TrialK Melissa Hallow, David W Boulton, Robert C Penland, et al.Interface Focus|April 7, 2016
Requirements for multi-level systems pharmacology models to reach end-usage: the case of type 2 diabetesElin Nyman, Yvonne J W Rozendaal, Gabriel Helmlinger, et al.Diabetes, Obesity & Metabolism|August 20, 2019
Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitorsTatiana Yakovleva, Victor Sokolov, Lulu Chu, et al.European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 17, 2017
Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meetGabriel Helmlinger, Nidal Al-Huniti, Sergey Aksenov, et al.Frontiers in Immunology|March 19, 2021
Evaluation of Combination Strategies for the A<sub>2A</sub>R Inhibitor AZD4635 Across Tumor Microenvironment Conditions <i>via</i> a Systems Pharmacology ModelVeronika Voronova, Kirill Peskov, Yuri Kosinsky, et al.CPT: Pharmacometrics & Systems Pharmacology|May 16, 2019
Quantitative Systems Pharmacology: An Exemplar Model-Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug DevelopmentGabriel Helmlinger, Victor Sokolov, Kirill Peskov, et al.Current Topics in Medicinal Chemistry|March 16, 2016
Implications of Dynamic Occupancy, Binding Kinetics, and Channel Gating Kinetics for hERG Blocker Safety Assessment and MitigationRobert A Pearlstein, K Andrew MacCannell, Gül Erdemli, et al.Molecular Therapy. Nucleic Acids|October 16, 2024
l-Type amino acid transporter 1-targeting nanoparticles for antisense oligonucleotide delivery to the CNSYu Na Lim, In Soo Ryu, Yeon-Joo Jung, et al.Pageof 5